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Background: Refractory blood loss is a common problem in surgeries for acute type A aortic dissections. Significant
evidence has supported the benefit of using recombinant activated factor VII (rFVIIa) to control of intractable bleeding
in patients after cardiac surgery. In this prospective clinical study, we present a novel method to achieve intraoperative
hemostasis by using a combination of platelets and rFVIIa during operations for acute type A aortic dissections.
Methods: Between May 2009 and August 2012, 71 patients with acute type A dissections who underwent emergency
surgery were prospectively included and allocated to one of the following two intervention groups for hemostasis: 3
units platelets combined with 2.4 mg rFVIIa (n = 25), and conventional methods (n = 46).
Results: The patients who received the combination of platelets and rFVIIa required fewer transfusions of red blood
cells (6.2 ± 3.1 units vs 9.8 ± 2.8 units; p < 0.05), fresh frozen plasma (736.9 ± 178.3 ml vs 1264.3 ± 245.2 ml, p < 0.05),
platelet concentrates (3 units vs 5.0 ± 1.8 units, p < 0.001), and cryoprecipitate (2.8 ± 0.9 units vs 8.2 ± 2.3 units, p < 0.05).
These patients also required less time for sternal closure (76.9 ± 17.2 min vs 102.3 ± 10.7 min, p < 0.05) compared with
the conventional therapy patients. There was no statistically significant difference in the incidence of serious adverse
events between these two groups.
Conclusions: Using a combination of platelets and rFVIIa is an effective strategy for achieving hemostasis during acute
type A dissection surgery. This hemostatic strategy does not appear to be associated with an increase in postoperative
adverse events.
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An acute type A aortic dissection is the most life-
threatening vascular emergency recognized to date. Since
this condition is associated with an 80% mortality rate,
every acute type A dissection requires emergency surgical
intervention to prevent aortic rupture and death [1].
One of the most serious problems during this surgery is
massive refractory blood loss. During surgery for a type
A dissection, the need for a complicated aortic anasto-
mosis; prolonged cardiopulmonary bypass (CPB) time;
and, particularly, deep hypothermic circulatory arrest
can induce platelet disorders, thereby increasing blood* Correspondence: xu6mouse@163.com
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unless otherwise stated.loss, increases the duration of the operation and results
in an increased requirement for transfusion of allogeneic
blood products. The conventional method for achieving
hemostasis includes the transfusion of fresh frozen plasma,
platelets, fibrinogen, and antithrombin, with the aim of
normalizing coagulation, while increasing platelet count
and function [2].
Recombinant activated factor VII (rFVIIa; NovoSeven,
Novo Nordisk, Bagsvaerd, Denmark) is a novel hemostatic
agent, which has been proven effective for the manage-
ment of hemorrhage after cardiac surgery [3-5]. Although
multiple studies have supported the efficacy and safety
of rFVIIa in cardiac operations [2-7], there are concerns
regarding the optimal dosage of rFVIIa and the timing
of rFVIIa administration [6,7]. There has not been any
evidence presented regarding a standardized protocolis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dissection.
The optimal dosages of rFVIIa, as described in the
literature, range from 11 to 100 μg/kg, and Gelsomino
et al. [4] presented the effectiveness of a 1.2-mg rFVIIa
dose in 40 patients with persistent blood loss.
We considered the function of a platelet in a hemostatic
procedure and tried to develop a hemostatic strategy that
used a combination of platelets and rFVIIa [6-9]. After
preliminary exploratory management, we selected a fixed
dose of platelets and rFVIIa for intraoperative use in acute
type A dissection surgery. In this study, we will present
the efficacy and safety of this strategy in comparison with
conventional hemostatic methods.
Methods
Patients and data collection
In the period from May 2009 to August 2012, 71 patients
with acute type A aortic dissections who underwent emer-
gency surgery at our institution (The Second Hospital of
Jilin University, Changchun, China) were prospectively
included in this non-randomized clinical study. The study
protocol was approved by the Ethics Committee of The
Second Hospital of Jilin University. We introduced in
details about the conventional hemostatic treatment and
this new strategy, and made a clear comparison between
them. We had made it clear and clarified to patients and
their families, and they should be capable to understand
the two different methods and make their decision
accordingly. They made their own decision preoperatively
about which hemostatic strategy would be used during
operation. Of these patients, 25 (35.2%) received the
combination of platelets and rFVIIa after cessation of
CPB, and the others received conventional hemostatic
treatment. All patient data were recorded according to a
standardized procedure established by our scientific com-
mittee. Data collected included patient demographics,
mortality, adverse events, and the use of blood products.
In addition, hematologic data such as the international
normalized ratio (INR) and activated partial thrombo-
plastin time (APTT) were collected. The amount of
time required for sternal closure was determined by the
difficulty in achieving hemostasis after separation from
CPB, so we chose this measurement to evaluate this
new hemostatic strategy.
Guidelines for the combination use of platelets and rfviia
during surgery
Acute type A dissection operations were performed as
previously described [10,11]. The platelet protective agent
tranexamic acid was bolus infused at 10 mg/kg at the
beginning of surgery, and another same dosage was given
after the protamine infusion in both two groups. In brief,
all the patients underwent median sternotomy, femoralartery cannulation, and total CPB. After CPB was estab-
lished, cooling was initiated. Cardiac arrest was accom-
plished by using cold cardioplegic solution after clamping
of the ascending aorta. For surgery that involved hemiarch
or total arch reconstruction, patients were cooled to 20°C
for a period of deep hypothermia. All the patients were
underwent Bentall or ascending replacement. Hemiarch
replacement or total arch replacement was performed
according to the condition of the arch after the tear. The
stent was implanted into the distal aorta as the stented
elephant trunk. In the control group, conventional methods
of achieving hemostasis were performed after separation
from CPB, which included the administration of red blood
cells, fresh frozen plasma, platelets, and cryoprecipitate. In
the platelet and rFVIIa combination group, 3 units of plate-
lets were quickly transfused after separation from CPB, and
then 2.4 mg (25.8 μg/kg–53.3 μg/kg) of rFVIIa was given
by the anesthetist. If adequate levels of hemostasis were not
achieved after platelet and rFVIIa administration, conven-
tional methods for achieving hemostasis, other than platelet
transfusion, which was performed only after the operation
was completed, were used.
Statistical analysis
All comparisons were performed between patients who
received conventional hemostatic therapy (control group)
and patients who received a combination of platelets and
rFVIIa (platelet and rFVIIa group). Values were presented
as mean ± standard deviation, median ± 25th–75th percent-
ile interquartile range, or percentages. Baseline patient
characteristics (including age, weight, gender, body surface
area, baseline laboratory values, American Society of An-
esthesiologists’ class, principal procedure performed, use
of deep hypothermic circulatory arrest, CPB time, nadir
hemoglobin levels during bypass, intraoperative perfusion,
and sternal closure time) were compared between the two
groups using the Χ2 test, Kruskal–Wallis test, and t-test.
Statistical significance was determined if the p value was
less than 0.05. Calculations were performed using the
SPSS software, version 19.0 (IBM, New York, USA).
Results
Patient characteristics
Table 1 highlights the demographic and clinical charac-
teristics of the 2 groups of patients. The distribution of
age, gender, height, weight, body surface area, baseline
laboratory values, use of deep hypothermia circulation
arrest, and CPB time was provided in Table 1. There were
no statistically significant differences between the control
and the platelet and rFVIIa group.
Intraoperative transfusions and the effect of the com-
bination of platelets and rFVIIa.
The patients who received the combination of platelets
and rFVIIa required fewer transfusions of red blood cells
Table 1 Demographic features of patients
Variable Control (n = 46) rFVIIa + platelet (n = 25) pValue
Age (years) 52.8 ± 10.3 53.7 ± 11.3 0.724
Male sex 31 (67%) 15 (60%) 0.607
Height (cm) 168.9 ± 8.3 167.3 ± 8.6 0.449
Weight (kg) 69.7 ± 11.8 71.4 ± 11.5 0.587
Body surface area (m2) 1.75 ± 0.16 1.78 ± 0.19 0.647
Baseline laboratory values
Hemoglobin (g/L) 130 ± 16 130 ± 21 0.979
Platelets counts (109cells/L) 172 ± 70 161 ± 53 0.499
International normalized ratio (INR) 1.00 ± 0.10 0.98 ± 0.09 0.305
Activated partial thromboplastin time (APTT) (sec) 26.6 ± 2.1 28.6 ± 1.0 0.964
Prothrombin time (PT) (sec) 11.9 ± 0.2 11.6 ± 0.2 0.368
D-dimer (ng/ml) 2147.8 ± 512.3 2497.5 ± 532.1 0.642
Creatinine (μmol/L) 83.1 ± 20.6 87.1 ± 32.7 0.554
ASA class
III 3(6.5%) 1(4.0%) 1
IV 43(93.5%) 24(96.0%) 1
Principal procedure
Bental 2(4.3%) 0(0%) 0.416
Ascending aortic replacement 3(6.5%) 2(8%) 1
Bental + hemiarch replacement 1(2.2%) 1(4%) 0.584
Ascending aortic + total arch replacement 3(6.5%) 0(0%) 0.492
Bental + total arch replacement + stent implanted 3(6.5%) 1(4%) 1
Ascending aortic + total arch replacement + stent implanted 34(73.9%) 21(84.0%) 0.331
Deep hypothermic circulatory arrest time (min) 49.5 ± 14.6 50.8 ± 11.4 0.711
Selective cerebralperfusion time (min) 43.8 ± 13.2 42.7 ± 11.1 0.724
Selective cerebralperfusion flow rate (ml/min) 492.2 ± 88.3 484.8 ± 93.6 0.743
Cardiopulmonary bypass time (min) 196.3 ± 41.8 191.4 ± 26.7 0.605
Nadir hemoglobin on bypass (g/dL) 7.3 ± 1.2 7.6 ± 0.9 0.267
Values expressed as average (standard deviation) or number (percent). ASA = American Society of Anesthesiologists.
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plasma (736.9 ± 178.3 ml vs 1264.3 ± 245.2 ml, p < 0.05),
platelet concentrate (3.0 units vs 5.0 ± 1.8 units, p < 0.001),
and cryoprecipitate (2.8 ± 0.9 units vs 8.2 ± 2.3 units,
p < 0.05) compared with the control group (Figure 1).
The sternal closure time was less in the platelet and
rFVIIa group as compared to the control group after
separation from CPB (76.9 ± 17.2 min vs 102.3 ± 10.7 min,
p < 0.05), which indicates that this new strategy achieves
better hemostasis than conventional hemostatic methods
(Figure 2).
Coagulation laboratory findings
On arrival in the ICU, the patients in the platelet and
rFVIIa group had better coagulation indicators (INR,
0.91 ± 0.11 vs 1.26 ± 0.21, p < 0.05; APTT, 31.6 ± 2.4 seconds
vs 39.8 ± 3.7 seconds, p < 0.05) than did the control grouppatients (Table 2). Both groups had similar body temp-
erature, and pH, hemoglobin, platelet, and fibrinogen levels.
Postoperative blood loss and transfusion requirements
The amount of blood loss was similar in the 2 groups at
1, 6, and 12 h after the operation (Table 3). Patients who
received the combination of platelets and rFVIIa required
fewer platelet concentrate transfusions (0 unit) as compared
to the control group patients on the first postoperative day
(median, 1 unit; interquartile range, 0–1 unit, p < 0.05) and
over the entire postoperative recovery period (median, 1
unit; interquartile range, 0–1 unit, p < 0.001; Table 3).
Serious adverse events
Total postoperative complications were equivalent be-
tween the 2 groups (Table 4). One patient (2.2%) in the
control group required reoperation on the first day after
Figure 1 Intraoperative blood product transfusions: A, B, C, and D bar graphs show the transfusions of red blood cells, fresh frozen
plasma, platelet concentrate, and cryoprecipitate, respectively. Data are mean ± SD (n = 46 in the control group; n = 25 in the rFVIIa + platelet
group). *p < 0.05 vs control group.
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in the control group and 2 patients (8%) in the platelet
and rFVIIa group developed arrhythmias in the ICU,
which were successfully corrected by administering the
appropriate therapy. There were 2 patients (4.3%) in theFigure 2 Sternal closure time: The bar graph represents the sternal cl
in the rFVIIa + platelet group). *p < 0.05 vs control group.control group and 1 patient (4%) in the platelet and rFVIIa
group who required continuous renal replacement therapy
for acute renal failure. There was 1 case of stroke each in
the control group (2.2%) and in the platelet and rFVIIa
group (4%), both caused by cerebrovascular ischemicosure time. Data are mean ± SD (n = 46 in the control group; n = 25
Table 2 Postoperative laboratory data
Variable Control(n = 46)
rFVII + platelet
(n = 25) pValue
Temperature (°C) 35.9 ± 0.7 35.9 ± 0.5 0.881
pH 7.41 ± 0.13 7.41 ± 0.13 0.573
Hemoglobin (g/L) 99.8 ± 12.7 104.2 ± 17.5 0.246
Platelets (109cells/L) 197.4 ± 73.3 184.1 ± 77.4 0.492
International normalized
ratio (INR)
1.26 ± 0.21 0.91 ± 0.11 0.008
Activated partial
thromboplastin time (sec)
39.8 ± 3.7 31.6 ± 2.4 0.019
Fibrinogen (g/L) 3.02 ± 0.45 2.87 ± 0.32 0.231
Values are expressed as average (standard deviation).
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died of renal failure, and 1 patient (4%) in the platelet
and rFVIIa group died of stroke. The complications
were not investigated and did not appear to be caused
by thromboembolism or rFVIIa administration.
Follow-up
There were three deaths during a mean follow-up of
33 ± 16 months in control group. One patient died of
unknown cause 18 months after surgery. One patient who
underwent Bental and total arch replacement combined
with stent implanted received thoracoabdominal aortic
replacement operation 3 years after primary surgery, and
died of renal function failure. One patient died of acute
myocardial infarction 2 years after surgery. There was one
death during a mean follow-up of 30 ± 14 months in plate-
let and rFVIIa group, who died of liver cancer 3 years after
surgery. The platelet and rFVIIa group had similar death
rate as control group during this short follow-up (3 (6.8%)
vs 1 (4.2%), p > 0.05)).Table 3 Postoperative bleeding and transfusions
Variable Control (n = 46)
1-hour chest tube drainage (ml) 63.6 ± 29.7
6-hour chest tube drainage (ml) 229.5 ± 150.1
12-hour chest tube drainage (ml) 336.3 ± 189.1
Transfusions: postoperative day 0
Red blood cell (units) 3(2–4)
Fresh frozen plasma (ml) 600(300–820)
Platelet concentrate (units) 1(0–1)
Cryoprecipitate (units) 0
Transfusions: Total postoperative
Red blood cell (units) 3(2–5.5)
Fresh frozen plasma (ml) 700(500–1400)
Platelet concentrate (units) 1(0–1)
Cryoprecipitate (units) 0
Values are expressed as average (standard deviation) or median (interquartile rangeDiscussion
In this report, we have presented the results of administer-
ing a combination of platelets and rFVIIa during surgery
for acute type A aortic dissections; this new strategy is
intended to improve coagulation after separation from
CPB, resulting in a reduced need for blood product trans-
fusions and shorter sternal closure time. Our findings
demonstrated that the administration of platelet supple-
ments first, followed by a low dose of intravenous rFVIIa,
significantly improved hemostasis, with few serious adverse
events and no obvious increase in adverse events as com-
pared to conventional hemostatic therapy.
Acute type A aortic dissection is the most lethal cardio-
vascular emergency, and uncontrolled hemorrhage is a
serious, most often fatal, problem in acute type A dissec-
tion surgery. Activated factor VII is a naturally occurring
initiator of hemostasis, and administration of rFVIIa
has become a new tool in the management of critical
hemorrhage associated with cardiovascular surgery. Many
studies have reportedly proven that the rFVIIa is a safe
and effective treatment for haemorrhage after cardiac
surgery, but the dosage selection is still a controversy
[7,12,13]. There have been many previous reports on the
appropriate dose of rFVIIa in cardiac surgery, and the use
of a low dose has been accepted in most institutions
[14,15]. We tried to establish a procedure to control
hemorrhage after separation from CPB that involves the
use of a low dose of rFVIIa. In our previous clinical
experience with hemostasis, we found that platelet sup-
plementation could improve the outcome of a single
administration of rFVIIa. Before this strategy formation,
we infused 1 unit of platelets and 1.2 mg of rFVIIa after
separation from CPB, but we also needed to transfuse
similar count of platelets and other blood products as
before. Two units of platelet transfusion could significantlyrFVII + Platelet (n = 25) pValue
52.5 ± 31.5 0.204
157.5 ± 94.2 0.227







0 P < 0.001
0 0.180
).
Table 4 Adverse events
Complication Control(n = 46)
rFVII + platelet
(n = 25) pValue
Reoperation for bleeding 1(2.2%) 0 0.648
Delayed sternal closure 0 0 1
Sternal infection 0 0 1
Postoperative arrhythmia 3(6.5%) 2(8%) 0.581
Acute renal failure 2(4.3%) 1(4%) 0.718
Myocardial infarction 0 0 1
Pulmonary embolism 0 0 1
Mesenteric ischemia 0 0 1
Any stroke 1(2.2%) 1(4%) 0.584
Embolic stroke 0 0 1
Permanent paraparesis 1(2.2%) 0 0.648
Over 7 days stay in ICU 5(10.9%) 2(8%) 0.526
30-day/in-hospital death 2(4.3%) 1(4%) 0.718
Values are expressed as number (percent).
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and 2.4 mg of rFVIIa, and it happened more than once. It
is because of this that we designed a new hemostatic strat-
egy that uses a combination of three units of platelets and
2.4 mg of rFVIIa to optimize hemostatic effects. After using
this new strategy, we did not need to administer either add-
itional platelets or rFVIIa, and we could obtain satisfactory
hemostasis for sternal closure. When this study was de-
signed, we also wanted to compare only platelet therapy
and combination of platelet and rFVIIa therapy. However,
during the operation process, when the only platelet ther-
apy did not have satisfactory haemostatic results, some
fresh frozen plasma and cryoprecipitate had to be used
since we did not have unlimited access of platelet in our
country. In the combination of platelet and rFVIIa therapy
group, we also needed to use some fresh frozen plasma and
cryoprecipitate. We had to try our best to get the best
haemostatic result and finish the surgery as soon as possible
to decrease surgical complications in both two groups.
Multiple complications related to hemostasis such as
platelet dysfunction, generalized coagulation factor defi-
ciency, and fibrinolysis can develop after acute type A
dissection surgery and can contribute to coagulopathic
bleeding. All of these hemostatic complications may be
caused by prolonged duration on CPB and in deep
hypothermia circulation arrest [7,16,17]. As a reportedly
effective method for organ function protection during
acute type A aortic dissection surgery, the deep hypo-
thermia was extensively used during the surgery [11].
Tissue factor is an integral membrane protein that is a
promoter of the coagulation cascade. The widely accepted
consensus on coagulation and thrombosis is that with
injury, vascular wall tissue factor is exposed to flowing
blood and it forms a complex with factor VII/VIIa. Arterialthrombosis and the proliferation of thrombi require that
a sequence of coagulation reactions as well as platelet
deposition occur on the thrombus surface. Adding
pharmacologic concentrations of rFVIIa to hemophilic
blood markedly increases platelet activation in the absence
of tissue factor and decreases the tissue factor-independ-
ent APTT and tissue factor-relative prothrombin time
[16,18,19]. Therefore, the administration of a combination
of additional platelets and rFVIIa could significantly
improve coagulation reactions, better than a single admin-
istration of either platelets or rFVIIa alone. We obtained
the corresponding conclusion from this study, in which
we provide a new protocol for hemostasis.
The most important unresolved problem in hemostasis
is whether rFVIIa is safe. After aortic surgery with CPB
and deep hypothermia arrest, tissue factor expression is
upregulated both systemically and in the areas of tissue
injury [20]. Since the mechanism of rFVIIa involves
binding to tissue factor, increased tissue factor expression
could lead to more local and systemic thrombus formation
[21]. Multiple studies have reported the safe use of rFVIIa
in adults undergoing cardiac operations, but the lack of
control patients in most of the studies makes it difficult to
determine whether the adverse events are related to the
use of rFVIIa or to the high-risk, unstable condition of
patients when they receive rFVIIa. Few studies have
suggested that the patients who received rFVIIa could
have an increase in the number of serious adverse events,
including stroke, length of hospital stay, and mortality
[17,22,23]. A review of adverse events reported to the U.
S. Food and Drug Administration suggests that most
thromboembolic events, with serious morbidity and
mortality, are related to the use of rFVIIa for “off-label”
indications [24]. In our study, overall rates of adverse
events were low and were equivalent in the treatment
and control groups. Low-dose rFVIIa administration is
recommended by some reports, which found that the
use of lower rFVIIa doses was much safer. Using the
lowest possible dose is warranted not only because of
the expense of factor rFVIIa, but also because of the
potential thromboembolic events [25]. The dose selected
in our study (25.8 μg/kg–53.3 μg/kg) is as low as Nicholas
D reported, and this dosage is safe and effective without
any thromboembolic adverse events [15]. As a kind of
component of blood, platelet is safe to be transfused to
patient in the same blood type. However, whether the over
dosed platelet transfusion would induce thromboembolic
or other relevant adverse events still need to be identified
in our future study. Although the cost-effectiveness out-
come was not the primary aim of the current study, we
did noticed that the cost of rFactor VIIa and blood prod-
ucts in treatment group was more than the cost of blood
products in control group ($4145.9 ± 355.7 vs $3114.7 ±
847.5, p < 0.05), because the cost of rFactor VIIa at this
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could not be offset by the decreased use of blood prod-
ucts, our study remain of significance in that considerable
blood products could be saved following the administra-
tion of platelet and rFactor VIIa. Although the overall cost
may be high in the treatment, the saved blood products
are definitely of value to the treatment of many other
clinical conditions, such as acute hemorrhage. The blood
products supply is always not enough, even seriously lack
in some area, so this new strategy has important positive
effect in countries and/or areas that are lack of some
blood products.
The major limitation of this study is the small sample
size and the lack of mechanistic research to determine
the dosages of platelets and rFVIIa selected. This new
hemostatic strategy was designed by using clinical experi-
ence, and it lacks laboratory study support. In addition, we
did not include the data regarding the incidence of hep-
arin induced thrombocytopenia and thrombosis (HITT)
in our analyses; therefore, the incidences of HITT in both
groups were unavailable. Moreover, we could not confirm
the causes of the 2 cases of ischemic stroke (1 in each
group). Judged from the clinical manifestation of the 2
patients and based on our experiences, HITT may be a
possible reason for the stroke, and the impacts of cerebral
hypo-perfusion and congenital cerebral malformation could
also not be ignored. Despite of these limitations, this study
is the first report of hemostatic strategy with confirmed
transfusion guidelines, uniform practice, and administration
of a low dose of rFVIIa.Conclusions
This prospective report describes a novel hemostatic strat-
egy for the administration of a combination of platelets
and rFVIIa during operations for acute type A aortic
dissections, which is intended to improve intraoperative
hemostasis, reduce the need for blood product transfusions,
and shorten sternal closure time without a significant
increase in adverse events.
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